Solid Tumor Therapeutics Market

SKU: DMPH457 | Last Updated On: Dec 01 2021 | No. of Pages: 180 | Available Formats

Global Solid Tumor Therapeutics Market Expected to reach a high CAGR of 16.0% By 2028: DataM Intelligence

Global Solid Tumor Therapeutics Market is segmented by Cancer Type (Prostate Cancer, Colorectal Cancer, Lung Cancer, Breast Cancer, and Others), By Drug Type (Bevacizumab (Avastin), Everolimusa (Afinitor), Cabazitaxel (Jevtana), Sunitinib (Sutent) and Others), By Treatment (Chemotherapy, Surgery, Radiotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028.


Market Overview

The Global Solid Tumor Therapeutics Market is expected to grow at a high CAGR of 16.0% during the forecasting period (2021-2028).

  • Solid Tumors are the result of the accumulation of abnormal tissues which doesn’t have liquid or cyst. They are mainly of three types namely Benign (Non-Cancerous), Premalignant and Malignant (Cancerous).

Market Size

  • The global robust tumor therapeutics market is growing due to several factors such as the rising prevalence of cases of solid tumors, increasing demand for advanced, effective chemotherapeutic drugs and therapies. According to WHO, in 2018, it was estimated that 164,690 men in the United States would develop prostate cancer.

Market Growth and Restraints

  • However, the increasing number of drugs going off-patent, the rising cost of R&D, the number of growing generic products, and the high cost of therapy are hindering the growth of the market. For instance, the patent for Pemetrexed expired in Japan and major European countries in December 2015, while the United States patent expired in January 2017.

Market Segmentation

The Solid Tumor Therapeutics market can be classified into cancer type, treatment type, drugs type.

By Cancer Type:

Prostate cancer

• Colorectal Cancer

• Lung Cancer

• Breast Cancer

• Cervical Cancer

• Brain Cancer

• Other Cancers

By Treatment:

• Chemotherapy

• Surgery

• Radiotherapy

• Other Treatments

Some of the major drugs for the treatment of solid tumors include Avastin (bevacizumab), Jevtana (cabazitaxel), Afinitor (everolimus), Tarceva (erlotinib), Sutent (sunitinib), Taxotere (docetaxel), Zytiga (abiraterone acetate), and others.

Geographically Analysis

  • Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is dominating the stable tumor therapeutics market holding the highest market share due to the availability of high-quality advanced healthcare systems in the United States. The asia-pacific market is also growing due to rising awareness and advancements in healthcare infrastructure for the treatment of various cases of cancer.

Market Key Companies

  • The major players include Abbott Laboratories, Inc., Amgen, Inc., AstraZeneca PLC, Baxter International, Inc., Biogen, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F.F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC, among others.

  • In June 2018, Aminex Therapeutics, Inc., a clinical-stage drug development company received clearance from the FDA to initiate the first Phase 1 clinical trial of its immuno-oncology drug candidate AMXT 1501, for treatment of advanced solid tumor cancer cases.

Key points covered in the report

  • Research Scope

  • Robust Tumor Therapeutics Product Pipeline Analysis

  • Solid Tumor Therapeutics Product Sales

  • Solid Tumor Therapeutics Market Value

  • Stable Tumor Therapeutics Market Share by Geography and Product type

  • Solid Tumor Therapeutics Epidemiology

  • Solid Tumor Therapeutics Product Analysis

Target Audience

• Raw Material Suppliers/ Buyers

• Product Suppliers/ Buyers

• Industry Investors/Investment Bankers

Education & Research Institutes

• Research Professionals

• Emerging Companies

• Manufacturers


Why purchase the report?

• Visualize the composition of the Global Solid Tumor Therapeutics market across each indication, regarding type and applications, highlighting the critical commercial assets and players.

• Identify business opportunities in Global Solid Tumor Therapeutics by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of the Global Solid Tumor Therapeutics market-level 4/5 segmentation

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study

• Product mapping in excel for the critical Global Solid Tumor Therapeutics products of all major market players

Trending Topics

Xerostomia Therapeutics Market

Pruritus Therapeutics Market


Table of Contents

1. Global Solid Tumor Therapeutics Market Scope and Methodology

1.1 Research methodology

1.2 Scope of the Report

2. Global Solid Tumor Therapeutics Industry Trends

3. Global Solid Tumor Therapeutics Market Outlook

3.1 Market Drivers

3.2 Market Restraints

3.3 Porters Five Forces Analysis

3.3.1 Suppliers Power

3.3.2 Buyer Power

3.3.3 Industry Competition

3.3.4 Threat of new Entrant

3.3.5 Threat of Substitutes 

4. Clinical Trial Analysis

5. Product Pipeline Analysis

6. Epidemiology Analysis

7. Segmentation by Cancer Type

7.1 Prostate Cancer

7.2 Colorectal Cancer

7.3 Lung Cancer

7.4 Breast Cancer

7.5 Cervical Cancer

7.6 Brain Cancer

7.6 Others

8. Segmentation by Drug Type

8.1 Bevacizumab (Avastin)

8.2 Everolimusa (Afinitor)

8.3 Cabazitaxel (Jevtana)

8.4 Sunitinib (Sutent)

8.5 Doxorubicin

8.6 Cisplatin

8.7 Erlotinib (Tarceva)

8.8 Paclitaxel

8.9 Gemcitabine

8.10 Docetaxel (Taxotere)

8.11 Abiraterone Acetate (Zytiga)

8.12 Carboplatin

8.13 Others

9. Segmentation by Treatment

9.1 Chemotherapy

9.2 Surgery

9.3 Radiotherapy

9.4 Others

10. Geographical Analysis

10.1 North America

10.1.1 United States

10.1.2 Canada

10.1.3 Mexico

10.2 Europe

10.2.1 United Kingdom

10.2.2 Spain

10.2.3 Germany

10.2.4 France

10.2.5 Rest of Europe

10.3 Asia-Pacific

10.3.1 India

10.3.2 China

10.3.3 Australia

10.3.4 Japan

10.3.5 Rest of Asia-Pacific

10.4 South America

10.4.1 Brazil

10.4.2 Argentina

10.4.3 Rest of South America

10.5 Rest of the World

11. Competitive Analysis

11.1 Market Player Analysis

11.2 Company Benchmarking

11.3 Key Strategies Adopted by Major Companies

12. Company Profiles*

12.1 F. Hoffmann-La Roche Ltd.

12.2 Baxter International, Inc.

12.3 Eli Lilly and Company

12.4 Bristol-Myers Squibb Company

12.5 Abbott Laboratories, Inc.

12.6 Amgen, Inc.

12.7 AstraZeneca PLC

12.8 GlaxoSmithKline Plc

12.9 Boehringer Ingelheim GmbH

12.10 Biogen, Inc 

13. Appendix

*Note: Additional company profiles will be included on request

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!